American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • An open-label, multi-center phase 2 study to assess the safety and efficacy of burixafor (GPC-100) and propranolol with G-CSF for the mobilization of stem cells in patients with multiple myeloma undergoing autologous stem cell transplant
    Meeting Abstract

    Caculitan, N.; Kim, G.; Woolfrey, A.; Akard, L. P.; Jeong, A. R.; Khouri, J.; Shah, G. L.; Cardarelli, P. M.
    Blood (2024)

    Fulltext@MSK | Save
  • Deep learning-driven 24-hour mortality risk assessment through peripheral blood smear morphology in hospitalized cancer patients
    Meeting Abstract

    Webb, D. C.; Colorado-Jimenez, C.; Fenelus, M.; Singi, S.; Yin, Z.; Paulsen, S.; Bilal, K. H.; Herskovitz, A. Z.; McCash, S.; Wang, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Advancing patient-centered care to overcome health disparities in multiple myeloma: key findings from a quality improvement initiative
    Meeting Abstract

    Mikhael, J.; Rodriguez, C.; Pierre, A. E.; Nawaz, M. S.; Moses-Okwei, E.; Gurska, L.; Zyborowicz, E.; Sullivan, S.; Carter, J.; Heggen, C.
    Blood (2024)

    Fulltext@MSK | Save
  • Manufacture of anti-BCMA CAR T cell is feasible after salvage autologous or allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Shah, G. L.; Perica, K.; Nagel, K.; Payson, E.; Hosszu, K. K.; Chung, D. J.; Landau, H. J.; Scordo, M.; Hultcrantz, M.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Delayed neurotoxicity after CAR-T in multiple myeloma: Results from a global IMWG registry
    Meeting Abstract

    Kumar, A. D.; Atallah-Yunes, S. A.; Rajeeve, S.; Abdelhak, A.; Hashmi, H.; Corraes, A.; Htut, M.; Rodriguez-Otero, P.; Parrondo, R. D.; Chhabra, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Mitochondrial augmentation of hematopoietic stem and progenitor cells as a new therapeutic approach for myelodysplasia
    Meeting Abstract

    Fujino, T.; Avni, N.; Kutner, N.; Khoury, H.; Pozner, G.; Sabath, N.; Castro, C.; Fox, N.; Lewis, A. M.; Tittley, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Safety and efficacy of belantamab mafadotin in patients with relapsed/refractory multiple myeloma: A real-world experience
    Meeting Abstract

    Dileo, R.; Mewawalla, P.; Patrus, G.; Strouse, C.; Chen, E.; Shaikh, H.; Davis, J. A.; Green, K. M.; Alkharabsheh, O.; Rashid, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Biomarker correlates and clinical activity of cevostamab in patients (pts) with triple-class refractory multiple myeloma (MM) who have received ≥1 prior B-cell maturation antigen (BCMA)-targeted bispecific antibody (BsAb): Results from the phase I/II CAMMA 2 study
    Meeting Abstract

    Delforge, M.; Richter, J.; Cohen, Y. C.; Corradini, P.; Sborov, D. W.; Lesokhin, A. M.; Berdeja, J. G.; Gatt, M. E.; Paris, L.; Dachs, L. R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • MagnetisMM-3: Long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Prince, H. M.; Bahlis, N. J.; Rodríguez-Otero, P.; Karlin, L.; Akard, L.; Varshavsky-Yanovsky, A.; Chu, M. P.; Nagai, Y.; Vesole, D. H.; Hickman, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Radiation therapy in a new era of multiple myeloma management: Trends of engagement and radiologic, biochemical, and cytogenetic correlates of outcomes and response
    Meeting Abstract

    Dreyfuss, A.; Fregonese, B.; Usmani, S. Z.; Mailankody, S.; Imber, B. S.; Yahalom, J.
    Blood (2024)

    Fulltext@MSK | Save